These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 21419125)

  • 41. Inhibition of IL-6 for the treatment of inflammatory diseases.
    Nishimoto N; Kishimoto T
    Curr Opin Pharmacol; 2004 Aug; 4(4):386-91. PubMed ID: 15251133
    [TBL] [Abstract][Full Text] [Related]  

  • 42. IL-6 in inflammation, immunity, and disease.
    Tanaka T; Narazaki M; Kishimoto T
    Cold Spring Harb Perspect Biol; 2014 Sep; 6(10):a016295. PubMed ID: 25190079
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tocilizumab, a humanized anti-IL-6R antibody, as an emerging therapeutic option for rheumatoid arthritis: molecular and cellular mechanistic insights.
    Hashizume M; Tan SL; Takano J; Ohsawa K; Hasada I; Hanasaki A; Ito I; Mihara M; Nishida K
    Int Rev Immunol; 2015 May; 34(3):265-79. PubMed ID: 25099958
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The value of blocking IL-6 outside of rheumatoid arthritis: current perspective.
    Murakami M; Nishimoto N
    Curr Opin Rheumatol; 2011 May; 23(3):273-7. PubMed ID: 21427577
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical pharmacology of tocilizumab for the treatment of patients with rheumatoid arthritis.
    Zhang X; Peck R
    Expert Rev Clin Pharmacol; 2011 Sep; 4(5):539-58. PubMed ID: 22114882
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The clinical efficacy of tocilizumab in rheumatoid arthritis.
    Mircic M; Kavanaugh A
    Drugs Today (Barc); 2009 Mar; 45(3):189-97. PubMed ID: 19436841
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Interleukin-6 receptor blockade selectively reduces IL-21 production by CD4 T cells and IgG4 autoantibodies in rheumatoid arthritis.
    Carbone G; Wilson A; Diehl SA; Bunn J; Cooper SM; Rincon M
    Int J Biol Sci; 2013; 9(3):279-88. PubMed ID: 23493630
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Interleukin-6 in idiopathic multicentric Castleman's disease after long-term tocilizumab.
    Akiyama M; Yasuoka H; Takeuchi T
    Ann Hematol; 2017 Dec; 96(12):2117-2119. PubMed ID: 28861599
    [No Abstract]   [Full Text] [Related]  

  • 49. Tocilizumab: molecular intervention therapy in children with systemic juvenile idiopathic arthritis.
    Yokota S; Kishimoto T
    Expert Rev Clin Immunol; 2010 Sep; 6(5):735-43. PubMed ID: 20828281
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman's disease.
    Matsuyama M; Suzuki T; Tsuboi H; Ito S; Mamura M; Goto D; Matsumoto I; Tsutsumi A; Sumida T
    Intern Med; 2007; 46(11):771-4. PubMed ID: 17541233
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Tocilizumab in rheumatoid arthritis].
    Rueda Gotor J; Blanco Alonso R
    Reumatol Clin; 2011 Mar; 6S3():S29-32. PubMed ID: 21794769
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tocilizumab - a novel therapy for non-organ-specific autoimmune diseases.
    Kaly L; Rosner I
    Best Pract Res Clin Rheumatol; 2012 Feb; 26(1):157-65. PubMed ID: 22424201
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Is interleukin-6 receptor blockade the Holy Grail for inflammatory diseases?
    Febbraio MA; Rose-John S; Pedersen BK
    Clin Pharmacol Ther; 2010 Apr; 87(4):396-8. PubMed ID: 20305672
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Recent advances in immunopathophysiology of interleukin-6: an innovative therapeutic drug, tocilizumab (recombinant humanized anti-human interleukin-6 receptor antibody), unveils the mysterious etiology of immune-mediated inflammatory diseases.
    Ohsugi Y
    Biol Pharm Bull; 2007 Nov; 30(11):2001-6. PubMed ID: 17978466
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Anti-interleukin 6 receptor antibody tocilizumab reduces the level of serum hepcidin in patients with multicentric Castleman's disease.
    Kawabata H; Tomosugi N; Kanda J; Tanaka Y; Yoshizaki K; Uchiyama T
    Haematologica; 2007 Jun; 92(6):857-8. PubMed ID: 17550864
    [TBL] [Abstract][Full Text] [Related]  

  • 56. MS arising during Tocilizumab therapy for rheumatoid arthritis.
    Beauchemin P; Carruthers R
    Mult Scler; 2016 Feb; 22(2):254-6. PubMed ID: 26743640
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses.
    Fujimoto M; Serada S; Mihara M; Uchiyama Y; Yoshida H; Koike N; Ohsugi Y; Nishikawa T; Ripley B; Kimura A; Kishimoto T; Naka T
    Arthritis Rheum; 2008 Dec; 58(12):3710-9. PubMed ID: 19035481
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [New approaches to pharmacotherapy for rheumatoid arthritis: perspective for use of tocilizumab (monoclonal antibodies to interleukin-6 receptor)].
    Nasonov EL
    Ter Arkh; 2010; 82(5):64-71. PubMed ID: 20597275
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tocilizumab in the treatment of myocardial infarction.
    Carroll MB
    Mod Rheumatol; 2018 Sep; 28(5):733-735. PubMed ID: 29334841
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The efficacy and safety of reinstitution of tocilizumab in patients with relapsed active rheumatoid arthritis after long-term withdrawal of tocilizumab: retreatment of patients with rheumatoid arthritis with novel anti-IL-6 receptor antibody after a long-term interval following SAMURAI: the RONIN study.
    Sagawa A
    Mod Rheumatol; 2011 Aug; 21(4):352-8. PubMed ID: 21347804
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.